Navigation Links
China Sky One Medical Announces Second Quarter 2011 Results
Date:8/9/2011

HARBIN, China, Aug. 9, 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One" or "the Company") (NASDAQ: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced financial results for the second quarter of 2011.

SecondQuarter 2011Financial Highlights

  • Total revenues decreased 7.6% year-over-year to $37.7 million
  • The Company marketed 101 products, compared with 114 products in the quarter ended June 30, 2010
  • Gross profit fell 15.7% to $24.9 million
  • Operating income declined 39.6% to $8.3 million
  • GAAP net income, including a non-cash gain from change in the fair value of derivative warrant liability, decreased 50.2% year-over-year to $6.1 million, or $0.36 per diluted share
  • Excluding the non-cash gain, non-GAAP adjusted net income declined 42.0% to $5.9 million, or $0.35 per diluted share

    • "Our second quarter revenue declined 7.6% year-over-year, primarily reflecting the loss of two distribution relationships in the third quarter of 2010. We continue to aggressively pursue new customers to distribute our broad portfolio of pharmaceutical products, while investing in China Sky One's future, as exemplified by our winning bid on land use rights for land in Harbin's Song Bei District. We intend to build a research and development center, an injection manufacturing facility, a logistics center and an office building on the land during the first phase of development, which we expect to complete by mid-2012," said Mr. Yan-Qing Liu, Chairman and CEO of China One Medical, Inc. "Despite the challenges of the past year, we are optimistic that we can reestablish robust revenue and earnings growth at China Sky One Medical by continuing to invest in R&D, securing new
    '/>"/>

    SOURCE China Sky One Medical, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
    2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
    3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
    4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
    5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
    6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
    7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
    8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
    9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
    10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
    11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/24/2013)... 24, 2013 China Biologic Products, Inc. (Nasdaq: ... integrated plasma-based biopharmaceutical company in China ... from a public announcement issued by Shanghai RAAS Blood ... on Shenzhen Stock Exchange, that on May 21, 2013, ... Chan"), one of the shareholders of the Company, and ...
    (Date:5/24/2013)... The potential of the pulmonary ... therapeutic agents has been receiving undeniable attention with the ... promise. The crucial formulation considerations for orally inhaled products ... major role in the efficiency of pulmonary delivery, and ... new formulation techniques and devices in recent years. ...
    (Date:5/23/2013)... SAN DIEGO y PARÍS, 24 de ... VOLC ), un destacado desarrollador y fabricante ... para mejorar la diagnosis y tratamiento de la ... resultados preliminares del ensayo ADVISE ( Ad enosine ... tenosis E valuation) II durante la sesión ...
    Breaking Medicine Technology:China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
    (Date:5/25/2013)... Texas (PRWEB) May 25, 2013 ... stressful than finals week. Increasingly, they are turning ... stay awake and study. For more on this, ... a drug treatment facility, warns that students who ... finals” are at risk for developing a physical ...
    (Date:5/25/2013)... Ayurveda is the traditional medicine ... wisdom of life". While a medical science, its scope enters ... consciousness. Its fundamental philosophy is that disease is the end ... believes that in order to re-establish optimal health, we must ... adopt a life style which brings us back into harmony. ...
    (Date:5/25/2013)... Flagstaff, Arizona (PRWEB) May 25, 2013 The ... Rehabilitation Center, their parents, and the B2B staff all came ... While everyone enjoyed an array of Indian Cuisine, the residents ... the company, for helping them on their road to recovery, ... started the Drug and Alcohol center in 2010 after realizing ...
    (Date:5/25/2013)... http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html , Resource4thePeople is ... of a jury's award of $6.5 million in damages ... the country over allegations that the diabetes drug Actos ... The judge in the case ruled that the man's ... was caused by the medication.** , Bloomberg News in ...
    (Date:5/25/2013)... 25, 2013 AdvantaClean of Pikes Peak ... services for a healthy home and business in Colorado ... damage , mold inspections, mold testing, mold removal ... and coil cleaning. , With over 120 offices nationwide, ... industry offering a full suite of services for commercial, ...
    Breaking Medicine News(10 mins):Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 3Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 4Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 2Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 3Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 4
    ... Grants New Indication for Bothersome Vaginal Symptom Associated,With ... estrogens) Vaginal Cream 0.5 g has been approved ... a new indication and a new less,frequent twice-weekly ... (painful sexual intercourse) announced Wyeth,Pharmaceuticals, a division of ...
    ... from patients with lung cancer and examining them under ... utilized to better tailor the chemotherapy treatments to improve ... according to a study presented at the 2008 Chicago ... IASLC and the University of Chicago., Cancer researchers have ...
    ... tumors of African-American non-small cell lung cancer patients are ... of the epidermal growth factor receptor (EGFR) gene and ... a study presented at the 2008 Chicago Multidisciplinary Symposium ... the University of Chicago., These genetic factors have been ...
    ... are one milliard of a metre in size are ... materials. There are also significant amounts of nanoparticles in ... their health effects, because only a very small portion ... and safety risks. Nanoparticles have even been dubbed the ...
    ... http://www.HealthCentral.com ) the leading collection of condition-specific,consumer ... a,broad initiative to sell advertising for any ... partners on a,non-exclusive basis and not require ... party rankings., "We are changing the ...
    ... those shoppers who,wake up at 4am on Black Friday? Not ... is important not to disturb your circadian rhythm and to ... body,operates better on a good night,s sleep which is why ... the day after Thanksgiving.", SSA retailers nationwide have an ...
    Cached Medicine News:Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 2Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 3Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 4Health News:Research demonstrates differing genetic makeup of lung cancer in African-American patients 2Health News:Nanoparticles trigger cell death? 2Health News:HealthCentral Announces New Condition-Specific Ad Service to Offer Marketers the Highest Qualified Audiences 2Health News:Don't Disturb Your Circadian Rhythm This Black Friday 'Sleep In, Nap Later,' says Specialty Sleep Association 2
    The K-ASSAY Fibrinogen Control is an assayed quality control material intended for use in monitoring the accuracy and precision of the quantitative determination of fibrinogen....
    The K-ASSAY Anti-Streptolysin O Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assay for quantifyi...
    Eppendorf expands its line of benchtop microcentrifuges with the 5418. This easy-to-use microcentrifuge features a certified aerosol-tight rotor and a unique, contoured rotor bowl design to reduce no...
    ... Directigen EZ Flu A+B test is a ... qualitative detection of influenza A and B ... swabs of symptomatic patients. The Directigen EZ ... such that influenza A viral antigens can ...
    Medicine Products: